Elranatamab: a new promising BispAb in multiple myeloma treatment.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-20 DOI:10.1080/14737140.2023.2236303

Karolina Kociszewska, Martyna Bednarczyk, Sebastian Grosicki

{"title":"Elranatamab: a new promising BispAb in multiple myeloma treatment.","authors":"Karolina Kociszewska, Martyna Bednarczyk, Sebastian Grosicki","doi":"10.1080/14737140.2023.2236303","DOIUrl":null,"url":null,"abstract":"Introduction: Multiple myeloma is a B-cell malignancy caused by proliferating plasma cells in the bone marrow microenvironment in collaboration with various cell lineage subsets and growth factors without any perfect regulation and tendency to clonal heterogeneity. Despite remarkable improvement in MM treatment and the overall survival of patients, multiple myeloma remains an incurable disease with the tendency to relapse. Therefore, there is an urgent need for new therapeutic options to provide a stabilized response to treatment with long-term duration.Areas covered: Elranatamab (PF-06863135), is a novel heterodimeric humanized full-length bispecific IgG2 kappa antibody derived from 2 mAbs, the anti-BCMA mAb (PF-06863058) and the anti-CD3 mAb (PF-06863059), not yet licensed in routine use. This binding affinity of elranatamab to BCMA and CD3 has been optimized to potentially prompt more potent T cell-mediated anti-myeloma activity. Subcutaneous (s.c.) administration of elranatamab is superior in comparison to intravenous (i.v.), thus it is associated with lower incidence of adverse events, even in higher doses.Expert opinion: Currently, elranatamab is being investigated in a few clinical studies, and the preliminary results are very encouraging. At the time of writing this review there were no full papers published and all of the data in the literature were based on abstract presentations which carry limitations.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"775-782"},"PeriodicalIF":2.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2236303","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Multiple myeloma is a B-cell malignancy caused by proliferating plasma cells in the bone marrow microenvironment in collaboration with various cell lineage subsets and growth factors without any perfect regulation and tendency to clonal heterogeneity. Despite remarkable improvement in MM treatment and the overall survival of patients, multiple myeloma remains an incurable disease with the tendency to relapse. Therefore, there is an urgent need for new therapeutic options to provide a stabilized response to treatment with long-term duration.

Areas covered: Elranatamab (PF-06863135), is a novel heterodimeric humanized full-length bispecific IgG2 kappa antibody derived from 2 mAbs, the anti-BCMA mAb (PF-06863058) and the anti-CD3 mAb (PF-06863059), not yet licensed in routine use. This binding affinity of elranatamab to BCMA and CD3 has been optimized to potentially prompt more potent T cell-mediated anti-myeloma activity. Subcutaneous (s.c.) administration of elranatamab is superior in comparison to intravenous (i.v.), thus it is associated with lower incidence of adverse events, even in higher doses.

Expert opinion: Currently, elranatamab is being investigated in a few clinical studies, and the preliminary results are very encouraging. At the time of writing this review there were no full papers published and all of the data in the literature were based on abstract presentations which carry limitations.

查看原文本刊更多论文

Elranatamab：一种在多发性骨髓瘤治疗中有前景的新的BispAb。

引言：多发性骨髓瘤是一种B细胞恶性肿瘤，由骨髓微环境中的浆细胞增殖与各种细胞谱系亚群和生长因子协同作用引起，没有任何完美的调节和克隆异质性的趋势。尽管多发性骨髓瘤的治疗和患者的总生存率有显著改善，但多发性骨瘤仍然是一种不可治愈的疾病，有复发的趋势。因此，迫切需要新的治疗选择，以提供长期稳定的治疗反应。涵盖领域：Elranatamab（PF-06863135）是一种新的异二聚体人源化全长双特异性IgG2κ抗体，来源于2种mAb，即抗BCMA mAb（PF-0686.3058）和抗CD3 mAb（PF-06863059），尚未获得常规使用许可。elranatamab与BCMA和CD3的这种结合亲和力已经被优化，以潜在地促进更有效的T细胞介导的抗骨髓瘤活性。与静脉注射（i.v.）相比，皮下注射（s.c.）elranatamab更优越，因此即使在更高剂量下，它也能降低不良事件的发生率。专家意见：目前，elranatamab正在一些临床研究中进行研究，初步结果非常令人鼓舞。在撰写本综述时，还没有发表完整的论文，文献中的所有数据都是基于有局限性的抽象陈述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.